| Dr Hannah Nicole Wilson, AUD | |
|
279 Kings Daughters Dr Ste 202, Frankfort, KY 40601-6562 | |
| (502) 226-6494 | |
| Not Available |
| Full Name | Dr Hannah Nicole Wilson |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 279 Kings Daughters Dr Ste 202, Frankfort, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982343364 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (Kentucky) | Secondary |
| 231H00000X | Audiologist | 277934 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hannah Nicole Wilson, AUD 9607 Ridgeside Dr Apt 4, Louisville, KY 40291-5600 Ph: (502) 498-0120 | Dr Hannah Nicole Wilson, AUD 279 Kings Daughters Dr Ste 202, Frankfort, KY 40601-6562 Ph: (502) 226-6494 |
News Archive
The Devex "Development Newswire" blog provides a comprehensive round-up of sessions, events, and reports from the third day (July 24) of the XIX International AIDS Conference (AIDS 2012) in Washington, D.C., including a summary of a session that discussed how Brazil, South Africa, India, and China contribute to the global AIDS response.
Scientists have discovered how bird flu adapts in patients, offering a new way to monitor the disease and prevent a pandemic, according to research published in the August issue of the Journal of General Virology.
A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes. The study, "The Effect of Hemispheric Specific Remediation Strategies on the Academic Performance Outcome of Children With ADD/ADHD," was conducted by a research team including, Gerry Leisman, Robert Melillo, Sharon Thum, Mark Ransom, Michael Orlando, Christopher Tice, and Frederick Carrick. The study appears in the current issue of the International Journal of Adolescent Medicine and Health.
Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.
› Verified 7 days ago
Bluegrass Hearing Clinic, Llc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 103 Diagnostic Dr Ste A, Frankfort, KY 40601 Phone: 502-352-2468 Fax: 859-987-3273 |